Several early-stage therapeutic candidates and clinical results signal advances against obesity, diabetes, and autoimmune disorders. Hanmi Holdings presented preclinical data on HM-15275, a GLP-1/GIP/glucagon receptor triple agonist for obesity. Beijing QL Biopharmaceutical’s monthly GLP-1 agent zovaglutide showed weight loss in Phase II obesity trial, now advancing to Phase III. Sanofi reported strong Phase IIa results for brivekimig, an immunology bispecific antibody for hidradenitis suppurativa. Luxa Biotechnology published positive outcomes from its first-in-human stem cell therapy trial for dry age-related macular degeneration (AMD).